Mandate

Vinge advises Biotage in connection with its acquisition of Astrea from KKR’s life science platform Gamma

Vinge advises Biotage AB (publ) (“Biotage”) in connection with its acquisition of Astrea Bioseparations (“Astrea”), a high-growth chromatography solutions provider from Gamma Biosciences (“Gamma”), a life sciences tools platform created and controlled by KKR.

The acquisition extends Biotage’s chromatography franchise into the higher-growth and larger bioprocessing segment, while also increasing exposure to biologics and advanced therapeutic customers.

The purchase price will be paid in new ordinary shares in Biotage, entailing that the KKR-controlled Gamma is expected to become the largest shareholder in Biotage, with an ownership of approximately 17 percent.

The transaction is subject to shareholder approval by the general meeting of Biotage and customary closing conditions, including approvals from the UK authorities.

Vinge’s team consisted of Matthias Pannier, Karl Klackenberg, Linus Adolfsson, Sebastian Saadieh, Elis Allmark (M&A), Dain Hård Nevonen, William Kåge, Joel Magnusson, Anna Svensson, Gabriel Chabo (Capital Markets), Sebastian Örndahl (Anti-trust), Sara Dahlros Sköld and Julia Hagelberg (VDR).

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025